Skip to main content

Table 4 Changes in HbA1c, BMI, serum lipids and creatinine, blood pressure and dose of antidiabetic drugs (n = 33)

From: Effects of a low-carbohydrate diet on glycemic control in outpatients with severe type 2 diabetes

  Baseline After 3 months After 6 months P
HbA1c (%) 10.9 ± 1.6 (9.0 – 14.4) 7.8 ± 1.5 (5.9 – 11.3) 7.4 ± 1.4 (5.5 – 12.7) < 0.001
BMI 23.8 ± 3.3 (18.0 – 33.8) 23.5 ± 3.4 (16.8 – 32.8) 23.5 ± 3.4 (17.1 – 32.7) 0.057
Serum LDL-cholesterol (mg/dl)* 142 ± 50 (51 – 260)   128 ± 34 (61 – 213) 0.036
Serum HDL-cholesterol (mg/dl)* 52 ± 14 (30 – 77)   59 ± 16 (34 – 94) 0.008
Serum triglyceride (mg/dl)* 182 ± 189 (50 – 823)   157 ± 178 (34 – 721) 0.39
Serum creatinine (mg/dl) 0.68 ± 0.20 (0.38 – 1.20)   0.71 ± 0.21 (0.44 – 1.25) 0.21
Systolic BP (mmHg) 138 ± 17 (104 – 175)   135 ± 14 (97 – 157) 0.24
Diastolic BP (mmHg) 81 ± 11 (59 – 102)   81 ± 11 (48 – 113) 0.64
Patients with antidiabetic drugs (n)     
   Glibenclamide n = 6 (4.0 mg) n = 3 (1.7 mg) n = 1 (2.5 mg)  
   Glimepiride n = 1 (3.0 mg) n = 2 (0.75 mg) n = 0 (0 mg)  
   Tolbutamide n = 0 (0 mg) n = 0 (0 mg) n = 1 (500 mg)  
   Metformin n = 0 (0 mg) n = 2 (500 mg) n = 5 (600 mg)  
   Nateglinide n = 2 (135 mg) n = 2 (180 mg) n = 0 (0 mg)  
   Pioglitazone n = 0 (0 mg) n = 0 (0 mg) n = 2 (30 mg)  
   Miglitol n = 1 (150 mg) n = 3 (100 mg) n = 7 (125 mg)  
  1. HbA1c: hemoglobin A1c; BMI: body mass index; BP: blood pressure. Values are means ± SD. The numbers in parenthesis in HbA1c, BMI, serum lipids, serum creatinine and blood pressure indicate ranges, and those in antidiabetic drugs show a mean daily dose. Two drop-out patients are included in the analysis.
  2. *: Four patients are excluded from serum lipids analysis because they received lipid-lowering drugs.